SEC Form 4 · accession 0001609351-17-000009
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey D Marrazzo
Officer — Chief Executive Officer · Director
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $56.17 | Jan 18, 2017 | A | 70,000 | A | — | Jan 17, 2027 | Common Stock | 70,000 | 70,000 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 18, 2017 | A | 20,000 | A | — | — | Common Stock | 20,000 | 40,000 | D |
Explanation of responses
- F125% vests January 18, 2018 and the remainder vests in equal annual installments over the following three years.
- F2Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date.